OKYO Pharma Ltd
OKYO Pharma Ltd is a U.S.-listed clinical-stage biopharmaceutical company focused on developing investigational therapies for neuropathic corneal pain and other anterior segment eye diseases. The company operates through drug development programs centered on urcosimod and related ophthalmology assets, with its ordinary shares listed on Nasdaq.
Liiketoiminta
Osuus liikevaihdostaClinical-stage drug candidates intended to treat NCP, a chronic ocular pain condition.
Investigational ophthalmic therapies aimed at diseases affecting the front part of the eye.
Internal R&D, trial planning, and regulatory development work for pipeline assets.
Asiakkaat
OKYO Pharma does not yet sell commercial products; its primary stakeholders are patients, ophthalmologists, and clinical investigators involved in its development programs. In a future commercialization scenario, the relevant customers would be physicians, specialty eye-care providers, and healthcare payers using approved ophthalmic therapies. For now, the company’s work is directed toward generating clinical evidence that supports eventual regulatory approval and physician adoption.
Patients participating in studies of urcosimod and other investigational eye therapies.
Specialist physicians and clinical sites that recruit patients and generate trial data.
Agencies reviewing safety and efficacy data needed for advancement to approval.
Eye specialists who could prescribe approved treatments if development succeeds.
Strategia
OKYO Pharma’s core strategy is to advance urcosimod through late-stage clinical development for neuropathic corneal pain and build evidence for potential registration. The company is also strengthening its ophthalmology-focused leadership and maintaining access to capital so it can execute longer-duration clinical programs. Its commercial value depends on generating differentiated clinical data in a niche eye-disease category with limited approved treatment options.
Late-stage data are the main value-creation step for a clinical-stage biotech.
A focused eye-disease portfolio can support follow-on development beyond the lead program.
Clinical trials and regulatory work require ongoing capital before any product revenue exists.
Maantiede
OKYO Pharma is headquartered in London and operates as a foreign private issuer listed in the United States on Nasdaq. Its development activities are organized around global clinical trial execution, with the company explicitly planning a global Phase 3 study for urcosimod. As a clinical-stage biotech, its geography matters mainly through trial-site selection, regulatory pathways, and access to capital markets rather than manufacturing footprint.
Riskit
OKYO Pharma is exposed to the usual clinical-stage biotech risks: trial failure, safety or efficacy concerns, regulatory delays, and the possibility that a lead asset never reaches commercialization. Because it has no marketed products, its value is also highly dependent on external financing and on the ability to generate positive clinical data in a narrow ophthalmology indication.
- Late-stage clinical failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
The company’s value depends on positive Phase 3 data for urcosimod.
Kohdistuu: Lead NCP program
- Dilution from future capital raisesVaikutus: KorkeaTodennäköisyys: Korkea
Clinical-stage companies typically fund operations through equity issuance.
Kohdistuu: Ongoing R&D and G&A funding
- Regulatory approval delay or denialVaikutus: KorkeaTodennäköisyys: Kohtalainen
Even successful trials require regulator acceptance of the evidence package.
Kohdistuu: Global Phase 3 and registration pathway
- Reimbursement and pricing pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Even approved ophthalmic drugs can face coverage limits and cost controls.
Kohdistuu: Future commercial launch
Kirjanpito
Harkinnanvaraiset erätClinical trial spend is expensed as incurred and drives reported losses.
Vaikutus: Directly affects operating loss and comparability between periods
Public-company reporting, legal, audit, and investor relations costs are meaningful for a small biotech.
Vaikutus: Can increase as headcount and compliance needs grow
Capital raises are central to funding the pipeline and change share count economics.
Vaikutus: Affects per-share analysis and ownership dilution
The company notes eligibility for tax cash credits tied to surrenderable losses.
Vaikutus: Can offset cash burn and influence tax line items
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Ocean Biomedical, Inc.
OCEA · Pharmaceutical Preparations
Oculis Holding AG
OCS · Pharmaceutical Preparations
Oculis Holding AG is a Switzerland-based biopharmaceutical company focused on therapies for neuro-ophthalmology and ophthalmology.
Kiora Pharmaceuticals, Inc
KPHMW · Pharmaceutical Preparations
EyePoint, Inc.
EYPT · Laboratory Analytical Instruments
Ocugen, Inc.
OCGN · Biological Products, (No Diagnostic Substances)
Vicore Pharma Holding AB
VCRE · Pharmaceutical Preparations
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases.
Päivitetty: 28.9.2026